Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

79 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model.
Ignatoski KM, Escara-Wilke JF, Dai JL, Lui A, Dougall W, Daignault S, Yao Z, Zhang J, Day ML, Sargent EE, Keller ET. Ignatoski KM, et al. Prostate. 2008 Jun 1;68(8):820-9. doi: 10.1002/pros.20744. Prostate. 2008. PMID: 18324676
RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J, Bryant R, Roudier M, Branstetter DG, Dougall WC. Canon J, et al. Breast Cancer Res Treat. 2012 Oct;135(3):771-80. doi: 10.1007/s10549-012-2222-2. Epub 2012 Aug 29. Breast Cancer Res Treat. 2012. PMID: 22926264
The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC, Chaisson M. Dougall WC, et al. Cancer Metastasis Rev. 2006 Dec;25(4):541-9. doi: 10.1007/s10555-006-9021-3. Cancer Metastasis Rev. 2006. PMID: 17180711 Review.
Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.
Chaisson ML, Branstetter DG, Derry JM, Armstrong AP, Tometsko ME, Takeda K, Akira S, Dougall WC. Chaisson ML, et al. J Biol Chem. 2004 Dec 24;279(52):54841-8. doi: 10.1074/jbc.M406392200. Epub 2004 Oct 14. J Biol Chem. 2004. PMID: 15485831
Targeting RANKL in metastasis.
Dougall WC, Holen I, González Suárez E. Dougall WC, et al. Bonekey Rep. 2014 Apr 9;3:519. doi: 10.1038/bonekey.2014.14. eCollection 2014. Bonekey Rep. 2014. PMID: 24795813 Free PMC article. Review.
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, Dubeau L, Cline M, Pan Y, Yi PC, Gareth Evans D, Jacobs IJ, Menon U, Wood CE, Dougall WC. Widschwendter M, et al. EBioMedicine. 2015 Sep 9;2(10):1331-9. doi: 10.1016/j.ebiom.2015.08.037. eCollection 2015 Oct. EBioMedicine. 2015. PMID: 26629528 Free PMC article. Clinical Trial.
The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
Goessl C, Katz L, Dougall WC, Kostenuik PJ, Zoog HB, Braun A, Dansey R, Wagman RB. Goessl C, et al. Ann N Y Acad Sci. 2012 Aug;1263:29-40. doi: 10.1111/j.1749-6632.2012.06674.x. Epub 2012 Jul 25. Ann N Y Acad Sci. 2012. PMID: 22831177 Review.
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK. Kostenuik PJ, et al. J Bone Miner Res. 2009 Feb;24(2):182-95. doi: 10.1359/jbmr.081112. J Bone Miner Res. 2009. PMID: 19016581
Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
Holland PM, Miller R, Jones J, Douangpanya H, Piasecki J, Roudier M, Dougall WC. Holland PM, et al. Cancer Biol Ther. 2010 Apr 1;9(7):539-50. doi: 10.4161/cbt.9.7.11266. Epub 2010 Apr 1. Cancer Biol Ther. 2010. PMID: 20150760
79 results
Jump to page